Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  824 results for ""Xenograft Model Antitumor Assays""

Your Filters

Subject : paclitaxel
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction.

  • Authors : Bhullar AS; Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy and Comprehensive Cancer Center. The Ohio State University, Columbus, OH 43210, USA; Interdisciplinary Biophysics Graduate Program, The Ohio State University, Columbus, OH 43210, USA.

Subjects: Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/drug therapy ; Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/pathology ; Extracellular Vesicles*/Extracellular Vesicles*/Extracellular Vesicles*/metabolism

  • Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Dec 04; Vol. 32 (12), pp. 4467-4481. Date of Electronic Publication: 2024 Oct 05.Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Targeting Galectin-1 Overcomes Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma.

  • Authors : Zhou L; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.

Subjects: Paclitaxel*/Paclitaxel*/Paclitaxel*/pharmacology ; Galectin 1*/Galectin 1*/Galectin 1*/metabolism ; Galectin 1*/Galectin 1*/Galectin 1*/genetics

  • Source: Cancer research [Cancer Res] 2024 Nov 15; Vol. 84 (22), pp. 3894-3908.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

PAR1 Is a Candidate Target for the Treatment of Peritoneal Dissemination in Gastric Cancer.

  • Authors : Fujimoto D; Department of Surgery, Teikyo University Hospital Mizonokuchi, Kawasaki, Japan .; Kobayashi H

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/metabolism

  • Source: Anticancer research [Anticancer Res] 2024 Nov; Vol. 44 (11), pp. 4857-4867.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.

  • Authors : Lin Y; Department of Obstetrics and Gynecology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, China.; Liu N

Subjects: Paclitaxel*/Paclitaxel*/Paclitaxel*/pharmacology ; Paclitaxel*/Paclitaxel*/Paclitaxel*/therapeutic use ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/virology

  • Source: Virology journal [Virol J] 2024 Oct 05; Vol. 21 (1), pp. 245. Date of Electronic Publication: 2024 Oct 05.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.

  • Authors : Chen Y; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas, USA.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Subjects: Histone Demethylases*/Histone Demethylases*/Histone Demethylases*/antagonists & inhibitors ; Histone Demethylases*/Histone Demethylases*/Histone Demethylases*/metabolism ; Histone Demethylases*/Histone Demethylases*/Histone Demethylases*/genetics

  • Source: Molecular carcinogenesis [Mol Carcinog] 2024 Oct; Vol. 63 (10), pp. 2026-2039. Date of Electronic Publication: 2024 Jul 11.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8811105 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer.

  • Authors : Xie CK; Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou, 350001, China.

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology ; Gemcitabine*

  • Source: Molecular cancer [Mol Cancer] 2024 Sep 30; Vol. 23 (1), pp. 215. Date of Electronic Publication: 2024 Sep 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.

  • Authors : Koh B; Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea; Medicinal Chemistry & Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea.

Subjects: Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/pathology ; Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/drug effects

  • Source: Gynecologic oncology [Gynecol Oncol] 2024 Sep; Vol. 188, pp. 60-70. Date of Electronic Publication: 2024 Jun 26.Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer.

  • Authors : Liu D; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Amsterdam UMC location University of Amsterdam, Department of Medical Oncology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands

Subjects: Paclitaxel*/Paclitaxel*/Paclitaxel*/pharmacology ; Paclitaxel*/Paclitaxel*/Paclitaxel*/administration & dosage ; Paclitaxel*/Paclitaxel*/Paclitaxel*/therapeutic use

  • Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Sep; Vol. 178, pp. 117261. Date of Electronic Publication: 2024 Aug 05.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.

  • Authors : Gu X; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08554, USA.; Majumder J

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/metabolism ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology

  • Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 19; Vol. 25 (10). Date of Electronic Publication: 2024 May 19.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel.

  • Authors : Jie KY; Department of Nephrology, Wenling First People\'s Hospital of Zhejiang. No. 333, Chuan'an road, Wenling city, Zhejiang province, 317500, People's Republic of China.; Wei CL

Subjects: Xenograft Model Antitumor Assays*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

  • Source: Frontiers in bioscience (Landmark edition) [Front Biosci (Landmark Ed)] 2019 Jun 01; Vol. 24 (8), pp. 1452-1461. Date of Electronic Publication: 2019 Jun 01.Publisher: IMR Press Country of Publication: Singapore NLM ID: 101612996 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  824 results for ""Xenograft Model Antitumor Assays""